Raymond Woo, Chief Technology Officer of Ceribell Inc., sold 1,979 shares of common stock on August 21 for a total of $47,535, according to regulatory filings. The disposal was executed at $24.02 per share and was attributed to tax withholding obligations related to the vesting of restricted stock units.
The transaction occurred as Ceribell's stock traded near its 52-week high of $25.33, following a 109% return over the past year. Woo's direct holdings after the sale total 194,729 shares, including 1,026 shares acquired on July 31 through the company's Employee Stock Purchase Plan.
Ceribell reported second-quarter fiscal 2026 revenue of $28.1 million, a 33% increase year-over-year driven by expansion in seizure detection and new product development for delirium monitoring and pediatric care. However, the company posted a loss of $0.51 per share, wider than the $0.36 loss forecast by analysts.
Account growth added 32 new customers in the quarter, slightly below Canaccord's estimate of 36, though utilization of existing units remained strong. Analysts at Canaccord maintained a buy rating while raising the price target from $25 to $26. BTIG similarly adjusted its target from $28 to $30, citing Ceribell's leadership in point-of-care EEG and recent FDA approvals for pediatric and neonatal indications.
InvestingPro analysis indicated the stock appeared overvalued at current levels based on fair value metrics.
